Global Reporting Initiative (GRI) G3.1 Allergan Index

Global Reporting Initiative (GRI) G3.1 Allergan IndexGRI Category # and Requirement1. Vision & Strategy About AllerganAnnual ReportR&DCorporate ResponsibilitiesResponsibility - EHSSustainability Performance Report pages 2 & 31.1 CEO Statement Annual ReportSustainability Performance Report pages 2 & 31.2 Description of Key Impacts, Risks andOpportunitiesForm 10-KResponsibility - EHSSustainability Performance Report2. Organizational Profile2.1 Name of the Company LeadershipHistoryAllergan IndexAnnual Report front cover, name and contact informationon the back cover2.2 Major Brands, Products and Services ProductsAnnual Report2.3 Business Areas and Operational Structure ProductsAnnual Report2.4 Location of Company’s Headquarters Global Locations – Irvine, California, USA2.5 Countries in which Organizations Main Operationsare LocatedGlobal Locations – Manufacturing and R&D are locatedin USA, Ireland, UK, France, Brazil, Costa Rica2.6 Nature of Ownership Form 10-K2.7 Markets ProductsAnnual Report2.8 Scale of the Company Form 10-K2.9 Significant Changes During the Reporting Period Form 10-K2.10 Awards Received in the Reporting Period Annual ReportEHS Awards3. Reporting Parameters3.1 Reporting Period Annual Report front cover, Allergan reports on acalendar year annual cycleSustainability Performance Report page 5, representscalendar year 2011 and was published on May 30, 20123.2 Date of Most Recent Previous Report Annual Report front coverSustainability Performance Report page 5, representscalendar year 2011 and was published on May 30, 2012

3.3 Reporting Cycle Annual Report Allergan reports on a calendar yearannual cycleSustainability Performance Report Allergan reportssustainability performance on an annual cycle3.4 Contact for Questions Regarding the Report Allergan Contact InformationMichael Whaley – Sr. Director, EHS at 714-246-5492 orWhaley_Michael@Allergan.com3.5 Process for Defining Report Content Responsibility - EHSGlobal Reporting Initiative3.6 Limits of the Reporting Procedure Annual ReportResponsibility - EHSSustainability Performance Report3.7 Limitations of the Scope of the Report Annual ReportResponsibility - EHSSustainability Performance Report3.8 Joint Ventures, Subsidiaries, Outsourcing Research and Development PipelineResearch and Development Collaborations3.9 Data Capture Annual ReportResponsibility - EHSSustainability Performance Report3.10 Changes in the Presentation of InformationCompared to Earlier Reports3.11 Changes in the Scope and Limitations of the Reportor in the Measurement Methods AppliedAnnual ReportResponsibility - EHSSustainability Performance ReportAnnual ReportResponsibility - EHSSustainability Performance Report3.12 Index According GRI with Links This document represents Allergan’s in accordancestatement with the GRI Index G33.13 Verification: External Verification of theStatementsAnnual ReportResponsibility - EHSSustainability Performance Report4. Management Obligations and Commitment Corporate GovernanceResearch and Development4.1 Governance Structure Corporate GovernanceCorporate GuidelinesAllergan BylawsLeadershipAllergan Corporate CharterAllergan Code of Conduct4.2 Independence of Supervisory Board Chairman Corporate GovernanceCorporate Guidelines

4.3 Governance Body and/or Independent Members ofManagement4.4 Mechanisms for Stockholders and Employees toProvide Recommendations to the Board of Managementor the Supervisory Board4.5 Linkage Between Board Management Compensationand Company Performance4.6 Mechanism in Place for the Governance Bodies toEnsure Avoidance of Conflicts of Interest4.7 Expertise of the Governance Bodies in SustainableIssues4.8 Mission Statements, Company Values and Codes ofConduct4.9 Procedures of the Board of Management orSupervisory Board for Overseeing SustainabilityPerformance4.10 Processes for Evaluating the Performance of theBoard of ManagementLeadershipCorporate GuidelinesAllergan BylawsAllergan Code of ConductCorporate GuidelinesAllergan BylawsAllergan Code of ConductCorporate GovernanceSustainability Performance ReportCorporate GuidelinesAllergan BylawsAllergan Code of ConductResearch and DevelopmentAllergan FoundationPatient ResourcesPhysician ResourcesProfessional AffiliationsEducational GrantsComplianceResponsibility - EHSSustainability Performance ReportAnnual ReportShareholder InformationSustainability Performance ReportAnnual ReportShareholder InformationCorporate GuidelinesAllergan BylawsAllergan Code of Conduct4.11 Implementation of the Precautionary Principle Sustainability Performance ReportAnnual ReportShareholder Information4.12 Support of External Initiatives Research and DevelopmentAllergan FoundationPatient ResourcesPhysician ResourcesProfessional AffiliationsEducational GrantsComplianceResponsibility - EHSSustainability Performance ReportAnnual ReportShareholder Information4.13 Principal Memberships in Industry and BusinessAssociationsResearch and DevelopmentAllergan FoundationPatient Resources

Physician ResourcesProfessional AffiliationsEducational GrantsComplianceResponsibility - EHSSustainability Performance ReportAnnual ReportShareholder Information4.14 Stakeholder Groups Engaged by the Organization Research and DevelopmentAllergan FoundationPatient ResourcesPhysician ResourcesProfessional AffiliationsEducational GrantsComplianceResponsibility - EHSSustainability Performance ReportAnnual ReportShareholder Information4.15 Selection of Stakeholders Research and DevelopmentAllergan FoundationPatient ResourcesPhysician ResourcesProfessional AffiliationsEducational GrantsComplianceResponsibility - EHSSustainability Performance ReportAnnual ReportShareholder Information4.16 Approaches to Stakeholder Dialogue(Type/Frequency)4.17 Statements on Key Concerns Raised byStakeholdersResearch and DevelopmentAllergan FoundationPatient ResourcesPhysician ResourcesProfessional AffiliationsEducational GrantsComplianceResponsibility - EHSSustainability Performance ReportAnnual ReportShareholder InformationResearch and DevelopmentAllergan FoundationPatient ResourcesPhysician ResourcesProfessional AffiliationsEducational GrantsComplianceResponsibility - EHSSustainability Performance ReportAnnual ReportShareholder Information

5. Performance IndicatorsEconomicsManagement ApproachEC1. Direct economic value generated and distributedincluding revenues, operating costs, employeecompensation, donations, other community investments,retained earnings and payments to capital providersand governments.EC2. Financial implications and other risks andopportunities for the organization’s activities due toclimate change.EC3. Coverage of the organization’s defined benefitplan obligations.EC4. Significant financial assistance received fromgovernment.EC5. Range of ratios of standard entry-level wagecompared to local minimum wage at significantlocations of operation.EC6. Policy, practices and proportion of spending onlocally-based suppliers at significant locations ofoperation.EC7. Procedures for local hiring and proportion ofsenior management hired from the local community atsignificant locations of operation.EC8. Development and impact of infrastructureinvestments and services provided primarily for publicbenefit through commercial, in-kind or pro bonoengagement.EC9. Understanding and describing significant indirecteconomic impacts, and including the extent of impacts.EcologyManagement ApproachEN1. Materials Used By Weight or Volume.Allergan OverviewEHSAllergan FoundationComplianceCareersResearch and DevelopmentProduct Safety and Animal TestingClient/Shareholder EarningsClient/Shareholder FinancialsCarbon Disclosure Project – Results; search for AllerganClient/Shareholder EarningsClient/Shareholder FinancialsClient/Shareholder EarningsClient/Shareholder FinancialsClient/Shareholder EarningsClient/Shareholder FinancialsClient/Shareholder EarningsClient/Shareholder FinancialsClient/Shareholder EarningsClient/Shareholder FinancialsClient/Shareholder EarningsClient/Shareholder FinancialsAllergan FoundationClient/Shareholder EarningsClient/Shareholder FinancialsAllergan IndexEHSAllergan FoundationComplianceCareersResearch and DevelopmentProduct Safety and Animal TestingEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the Report

EN2. Percentage Of Materials Used That Are RecycledInput Materials.EHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEN3. Direct energy consumption by primary energysource.EN4. Indirect energy consumption by primary source.EN5. Energy saved due to conservation and efficiencyimprovements.EN6. Initiatives to provide energy efficient or renewableenergy based products and services, and reductions inenergy requirements as a result of these initiatives.EN7. Initiatives to reduce indirect energy consumptionand results achieved.EN8. Total water withdrawal by source.EN9. Water sources significantly affected by waterwithdrawal.EN10. Percentage and total volume of water recycledand reused.EN11. Location And Size Of Land Owned, Leased, OrManaged In Biodiversity-Rich HabitatsEN12. Description of the significant activities, productsand services on biodiversity in protected areas and areasof high biodiversity value outside protected areas.EN13. Habitats protected or restored.EN14. Strategies, current actions and future plans formanaging impacts on biodiversity.EHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHS BiodiversityEHSResponsibility - EHSEHS BiodiversityEHSResponsibility - EHSEHS BiodiversityEHSResponsibility - EHSEHS Biodiversity

EN15. Number of ICUN Red List species and NationalConservation List species with habitats in areas affectedby operations, by level of extinction risk.EN16. Total direct and indirect greenhouse gasemissions by weight.EN17. Other relevant greenhouse gas emissions byweight.EN18. Initiatives to reduce greenhouse gas emissionsand results achieved.EN19. Emissions of ozone-depleting substances byweight.EN20. NO, SO, and other significant air emissions bytype and weight.EN21. Total water discharged by quality anddestination.EN22. Total weight of waste by type and disposalmethod.EN23. Total number and volume of significant spillsEN24. Weight of transported imported, exported ortreated waste deemed to be hazardous under terms ofthe Basel Convention annex I, II, III, & VIII, andpercentage of waste transported internationally.EN25. Identity, size, protected status, and biodiversityvalue for water bodies and related habitats significantlyaffected by the reporting organization’s discharges ofwater and runoff.EN26. Initiatives to mitigate environmental impacts ofproducts and services, and extent of impact ofmitigation.EN27. Percentage of products sold and their packagingmaterials that are reclaimed by category.EHSResponsibility - EHSEHS BiodiversityEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEmissions ReductionsEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportInitiativesEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the Report

EN28. Monetary value of significant fines and totalnumber of non-monetary sanctions for non-compliancewith environmental laws and regulations.EN29. Significant environmental impacts oftransporting products and other materials and goodsused for the organization’s operations, and transportingmembers of the workforce.EN30. Total environmental protection expenditures andinvestments by type.Social PerformanceManagement ApproachLA1. Total workforce by employment type, employmentcontract and region.LA2. Total number and rate of employee turnover byage group, gender and region.LA3. Benefits provided to full-time employees notprovided to part-time or temporary employees, bymajor operations.LA4. Percentage of employees covered by collectivebargaining agreements.LA5. Minimum notice periods regarding operationalchanges, including whether it is specified in collectiveagreements.LA6. Percentage of workforce represented in formalEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEHSResponsibility - EHSSustainability Performance Report; summary tablelocated in back of the ReportEnvironmental CostsHealth and Safety CostsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsResearch and DevelopmentProduct Safety and Animal TestingAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsSustainability Performance Report see page 23Allergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsSustainability Performance Report see page 23Allergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsEHS

management-employee health and safety committeesthat help monitor and advise on occupational health andsafety programs.LA7. Rates of injury, occupational diseases, lost days,absenteeism, and number of work-related fatalities byregion.LA8. Education, training, counseling, prevention, andrisk control programs in place to assist workforcemembers, their families, and community membersregarding serious diseases.LA9. Health and safety topics included in formalagreements with trade unions.LA10. Average hours of training per year per employeeby employee category.LA11. Programs for skills management and lifelonglearning that support the continued employability ofemployees and assist them in managing career endings.LA12. Percentage of employees receiving regularperformance and career development reviews.LA13. Composition of governance bodies andbreakdown of employees per category according togender, age group, minority group membership, andother indicators of diversity.LA14. Ratio of basic salary and remuneration of womento men by employee category, by significant locations ofoperation.Human Rights IndicatorsHR1. Percentage and total of significant investmentagreements that include human rights clauses or haveundergone human rights screening.Responsibility - EHSEHSResponsibility - EHSSustainability Performance Report; summary table foundon the last pages of the ReportEHSResponsibility - EHSSustainability Performance Report; summary table foundon the last pages of the ReportEHSResponsibility - EHSAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsSustainability Performance Report; summary table foundon the last pages of the ReportAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsSustainability Performance Report; summary table foundon the last pages of the ReportAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsSustainability Performance Report; summary table foundon the last pages of the ReportAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsSustainability Performance Report; summary table foundon the last pages of the ReportAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human Rights

HR2. Percentage of significant suppliers andcontractors that have undergone screening on humanrights and actions taken.HR3. Total hours of employee training on policies andprocedures concerning aspects of human rights that arerelevant to operations, including the percentage ofemployees trained.HR4. Total number of incidents of discrimination andactions taken.HR5. Operations identified in which the right toexercise freedom of association and collectivebargaining may be at significant risk, and actions takento support these rights.HR6. Operations identified for having significant risk ofchild labor, and measures taken to contribute to theelimination of child labor.HR7. Operations identified as having significant risk forincidents of forced or compulsory labor, and measuresto contribute to the elimination of forced andcompulsory labor.HR8. Percentage of security trained in theorganization’s policies and procedures concerningaspects of human rights that are relevant to operations.HR9. Total number of incidents of violations involvingrights of indigenous people and actions taken.HR10. Percentage and total number of operations thathave been subject to human rights reviews and/orimpact assessmentsHR11. Number of grievances filed, addressed andAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan Overview

esolved through formal grievance mechanisms.Societal IndicatorsSO1. Percentage of operations with local communityengagement, impact assessments and developmentprograms.SO2. Percentage and total number of business unitsanalyzed for risks related to corruption.SO3. Percentage of employees trained in theorganization’s anti-corruption policies and procedures.SO4. Actions taken in response to corruption.SO5. Public policy positions and participation in publicpolicy development and lobbying.SO6. Total value of financial and in-kind contributionsto political parties, politicians, and related institutionsby country.SO7. Total number of legal actions for anticompetitivebehavior, antitrust, and monopoly practices and theiroutcomes.SO8. Monetary value of significant fines and totalnumber of non-monetary penalties for non-compliancewith laws and regulations.SO9. Operations with significant potential or actualCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsSustainability Performance ReportAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Commitment to Human RightsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan Overview

negative impacts on local communities.SO10. Prevention and mitigation measures implementedin operations with significant potential or actualnegative impacts on local communities.Product StewardshipManagement ApproachPR1. Life cycle stages in which health and safetyimpacts of products and services are assessed forimprovement, and percentage of significant productsand service categories subject to such procedures.PR2. Total number of incidents of non-compliance withregulations and voluntary codes concerning health andsafety impacts of products and services during their lifecycle, by type of outcomes.PR3. Type of product and service information requiredby procedures, and percentage of products and servicessubject to such information requirements.PR4. Total number of incidents of non-compliance withregulatory and voluntary codes concerning product andservice information and labeling, by types of outcomes.PR5. Practices related to customer satisfaction,including results of surveys measuring customersatisfaction.PR6. Programs for adherence to laws, standards, andvoluntary codes related to marketing communications,including advertising, promotion, and sponsorship.Corporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsSustainability Performance ReportAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsSustainability Performance ReportAllergan InvestorsEHSAllergan FoundationComplianceCareersResearch and DevelopmentProduct Safety and Animal TestingAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial Reports

PR7. Total number of incidents of non-compliance withregulations and voluntary codes concerning marketingcommunications, including advertising, promotion, andsponsorship by type of outcome.PR8. Total number of substantiated complaintsregarding breaches of customer privacy and loss ofcustomer data.PR9. Monetary value of significant fines for noncompliancewith laws and regulations concerning theprovision and use of products and services.Allergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsAllergan OverviewCorporate ResponsibilitiesCareersCorporate GovernanceFinancial ReportsGRI Application Level:Self EvaluationReviewed by Third Party External OrganizationsReviewed by GRINotApplicable√√C C+ B B+ A A+√